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Abstract
Interaction with the chemokine receptor, CCR5, is a necessary precondition for maintaining HIV-
1 infection. Individuals with the CCR5-delta32 deletion who lack this receptor are highly resistant
to infection by the most common forms of HIV-1. We recently reported on the successful
transplantation in an HIV-1-positive patient of allogeneic stem cells homozygous for the CCR5-
delta32 allele, which stopped viral replication for more than 27 months without antiretroviral
therapy.
Here, we report on the results of a meeting regarding the potential implications and future
directions of stem cell-targeted HIV treatments. The meeting drew together an international panel
of hematologists, immunologists, HIV specialists and representatives from bone marrow donor
registries.
The meeting came to an agreement to support further attempts to use CCR5-delta32 deleted stem
cells, for example, prescreened cord blood stem cells, to treat probable HIV-1-positive patients
with malignancies. Furthermore, improvement of HIV-1 therapy that interferes with the entry
mechanism seems to be a promising approach in HIV-1-infected patients with no matching CCR5-
delta32 deleted donor.
Introduction
Entry of the HIV-1 into the host cells requires the interac-
tion of the viral envelope with the CD4 surface molecule
and certain co-receptors, predominantly represented by
the chemokine receptor, CCR5. Blocking the co-receptor
interaction of CCR5-tropic HIV-1 by small-molecule
antagonists proved to be highly efficacious, suppressing
HIV-1 replication in extensively pretreated patients with
multi-resistance and virological failure of preceding regi-
mens [1].
Previously, a 32 base pair deletion in the CCR5 gene
(CCR5-delta32), leading to a truncated gene product, had
been shown to confer marked protection against HIV-1
infection in homozygous individuals, while infected het-
erozygotes show substantially delayed progression of the
infection [2,3].
First case of long-term HIV control by stem cell 
transplantation
In the 12 February 2009 issue of the New England Journal
of Medicine, we reported on an HIV patient with acute
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myeloid leukemia who achieved long-term control of
HIV-1 after allogeneic hematopoietic stem cell transplan-
tation (alloHSCT) from a human leukocyte antigen (HLA)
matched unrelated donor homozygous for CCR5-delta32
[4]. The patient was classified as being in CDC Stage 2,
and had been on HAART for five years with a proportion
of CXCR4 using strains (×4) of 2.9% before transplanta-
tion.
Viral load remained below the limit of detection 27
months after transplantation, despite discontinuation of
antiretroviral therapy. This result underscores the essential
role of the CCR5 co-receptor in maintaining HIV replica-
tion and raises questions about the feasibility of HIV erad-
ication by stem cell transplantation-based approaches.
Expert panel discussed future directions
On 20 April 2009, an international panel of hematolo-
gists, HIV specialists and representatives from bone mar-
row donor registries (ZKRD Ulm, Germany, and BBMR,
Bristol and London, UK) and donor centres (DKMS,
Tübingen, Germany, and Stefan-Morsch-Stiftung, Birken-
feld, Germany) met at a Berlin venue to discuss potential
implications and potential future directions of research
that emerge from this breakthrough observation. The
workshop was encouraged by Malcolm Thomas, trustee of
the British Bone Marrow Donor Appeal, and was chaired
by E Thiel from the Medical Department III of the Charité
University Hospital, Berlin, Germany.
Combination antiretroviral therapy (ART) allows for
long-term suppression of HIV-1 replication below the
level of detection in the majority of patients, thus greatly
reducing the percentage of patients progressing to AIDS.
Life expectancy in HIV-infected patients treated with
HAART has increased in the past 10 years, although there
is considerable variability between subgroups of patients.
In high-income countries, the average life expectancy at
the age of 20 years for HIV-positive people receiving ART
is about two-thirds of that of the general population [5].
However, this success has required the development of
more than 20 antiretroviral drugs since the first isolation
of the virus 25 years ago, and a substantial number of
patients still end up with multi-resistant viruses and very
limited therapeutic options. As M Bickel (JW Goethe Uni-
versity, Frankfurt/M, Germany) emphasized in his talk,
drug resistance, side effects, comorbidity and adherence
now emerge as the main factors that limit treatment effi-
cacy.
Furthermore, it has been suggested that the maintenance
of viral reservoirs, for example, in gut-associated lym-
phoid tissues, play a major role in the persistence of HIV
[6]. Even today, patients are dying from HIV infection or
HIV-related diseases despite state-of-the-art antiretroviral
therapy. Long-term outcomes may be improved by start-
ing ART earlier, i.e., when CD4+ T cell count levels are
higher, but permanent abrogation of virus replication will
remain a medical need unmet by conventional therapeu-
tic approaches.
Since ART treatment costs in the range of €30,000 per
year, definitive therapies abolishing the need for life-long
antiviral treatment should be beneficial even in terms of
utilization of health-care resources.
Therapy with CCR5-negative stem cells
In the early 1980s, alloHSCT appeared to be attractive as
a therapy for HIV in patients with advanced disease
because it was thought to substitute depleted CD4 cells
and reduce the HIV reservoir via the conditioning myelo-
ablative therapy.
As G Hütter (Charité Berlin, Germany) pointed out in his
talk, previous attempts of alloHSCT in HIV patients with
hematological malignancies produced encouraging over-
all survival outcomes, but these therapies failed to provide
a benefit in terms of HIV viral load reduction without con-
tinued ART. At least, HIV infection did not progress
despite immunosuppression, and alloHSCT appears med-
ically feasible in HIV patients with ongoing ART [7].
The case reported by Hütter et al now provides a proof of
principle for CCR5-targeted stem cell therapies. CCR5-
delta32 status appears to have several beneficial effects on
the alloHSCT setting: previous analyses revealed that the
CCR5-delta32 allele appears to protect against acute graft
versus host disease (GVHD) and EBV reactivation [8,9].
In contrast, the consequences of transplanting CCR5-neg-
ative donor cells to CCR5-positive recipients have so far
not been fully elucidated. For example, the reduction of
GVHD in the CCR5-delta32 setting raises the question of
whether CCR5 negativity may be associated with a dimin-
ished graft versus leukemia effect. However, the patient
described by Hütter et al developed a GVHD, which is
somewhat reassuring in terms of the reactivity of CCR5-
negative lymphocytes. Still, the sudden acquired lack of
CCR5, in contrast to life-long absence of the chemokine
receptor, may have yet unknown detrimental effects,
which are not observed in hereditary CCR5-negative indi-
viduals because of compensatory adaptations of the
cytokine receptor network.
In the gut mucosa of the reported patient, CCR5-positive
macrophages were detected five months after transplanta-
tion. Although complete chimerism of the myeloid line-
age had not been reached at this time, viral rebound was
not observed. Mucosal macrophages are known to serve asJournal of the International AIDS Society 2009, 12:10 http://www.jiasociety.org/content/12/1/10
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long-term virus reservoirs, as T Schneider (Charité Berlin,
Germany) pointed out in his presentation. The case illus-
trates that eradication of the primary target cells may be
sufficient to prevent a rebound of viral replication form
these reservoirs.
Genotypic determination of co-receptor tropism by ultra-
deep sequencing before alloHSCT had revealed that the
patient harboured a minor fraction of X4 viruses, which
might have been expected to take over after elimination of
CCR5-positive lymphocytes. However, neither CCR5-
using nor CCR4-using variants have been detected in the
follow ups so far.
This raises the possibility that CCR5-delta32 expression
has a dominant negative effect on CXCR4-mediated viral
entry [10]. In addition, the shift to X4 variants seen in
some patients with long-standing infections may be a
gradual process in which CCR5-using viruses somehow
pave the way for X4-using variants, a process that may
have been prevented by the sudden withdrawal of the tar-
get cells.
Stem cell sources
The CCR5-delta32 allele is mostly limited to the caucasian
population, with the highest frequency being reached in
the north-eastern parts of Europe [11]. It is largely absent
in Africa, as well as in eastern and south-eastern Asia.
Prevalence of the homozygous carriers is in the range of
1% to 3% among caucasians. Future approaches to HIV
therapy by CCR5-negative alloHSCT may thus be limited
by the availability of HLA-matched donors in general and
in the non-caucasoid populations in particular.
C Müller illustrated this fact with data from the German
National Bone Marrow Donor Registry (ZKRD, Ulm, Ger-
many): a simulation study based on high-resolution HLA-
A, B and DRB1 haplotype frequencies reveals that with the
current registry size, about 75% of German patient will
find at least one allele-matching donor for these loci.
Assuming a prevalence of 3% CCR5-delta32 homozy-
gotes, the likelihood of finding a matched German donor
is reduced to 30% if donors carrying two CCR5-delta32
alleles are sought. Bringing this figure back up to 75%
would require an expansion or the donor pool by a factor
of at least 10.
However, this problem is alleviated by the worldwide
cooperation of stem cell registries in the Bone Marrow
Donors Worldwide and European Marrow Donor Infor-
mation System networks, which are currently in the proc-
ess of merging into one single global registry access
system. Biostatistics will become more and more effective
in using limited HLA typing information to narrow down
the set of potential donors for a given patient, so these
individuals could be tested for CCR5-delta32 before
costly confirmatory HLA typing is undertaken.
In an effort to facilitate CCR5-targeted stem cell therapy,
Chow et al established a cord blood bank with specimens
from 10,000 CCR5-screened donors [12]. However, this
source of stem cells has not been used for transplantation
in HIV patients yet. Cord blood may emerge as an impor-
tant source of CCR5-negative stem cells because they have
been used successfully, even in the situation of a partial
donor-recipient mismatch. However, this approach may
be complicated by the fact that cord stem cell transplanta-
tion in adults currently requires more than one cord
blood unit.
Donor recruitment
A major issue concerning the supply of CCR5-negative
stem cells is the donor information policy of the bone
marrow registries. Transplantation from units of umbili-
cal cord blood stem cell only requires 4/6 HLA matches at
HLA A, B and DR with Class I matches, which would
remarkably increase the probability of finding a matching
donor with CCR5-delta32 homozygosity.
C Navarrete (British Bone Marrow Registry, London, UK)
explained that in cord blood banks in particular, testing of
CCR5 status is mostly not covered by the informed con-
sent signed by mothers. Thus at present, it is not legally
acceptable to screen existing units post hoc for CCR5-neg-
ativity. The same applies to adult donor recruitment pro-
grammes: CCR5 status testing may not be currently
covered by the informed consent given by volunteers.
Information strategies must therefore be carefully devised
in order to avoid detrimental effects to volunteer-unre-
lated donor recruitment.
Using HIV resistance transgenes in stem cells
Another approach to the provision of HIV-resistant blood
cells is the introduction of resistance-conferring genes
into stem cells before transplantation. This is an attractive
option: it may be a once-in-a-lifetime treatment; it is
expected to obviate or greatly reduce the need of ART; and
it may be suitable for patients with restricted ART options
due to resistance or side effects.
Since it is not possible to achieve gene transfer into all
cells of a transplant, the therapeutic gene must confer a
selective advantage allowing for the expansion of the
transgenic cell pool in vivo, which then will then gradu-
ally replace virus-susceptible cells. This is best reached by
targeting steps in the viral life cycle that protect the trans-
genic cells from the cytopathic effects of viral components
produced inside the cell.Journal of the International AIDS Society 2009, 12:10 http://www.jiasociety.org/content/12/1/10
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However, gene therapy approaches using so-called Class II
target genes, i.e., those that inhibit the synthesis of virus
particles but still allow for proviral integration of infecting
virus, have largely been unsuccessful. Thus, targeting steps
before integration (Class I target genes), and inhibition of
entry in particular, is the most promising approach, a
notion of the long-term fate of hematopoietic cells carry-
ing transgenes directed against different steps in the viral
life cycle [13].
B Fehse (Department of Cellular and Gene Therapy
Research, Hamburg-Eppendorf, Germany) presented an
ongoing Phase I/II gene therapy trial in HIV-positive
patients. The transgene used in this study encodes a mem-
brane-anchored peptide (C46) that interferes with the
viral-cellular membrane fusion, mechanistically similar to
the fusion inhibitor enfuvirtide. A Phase I study using
transgenic T cells without conditioning regimen had
shown good tolerability and long-term survival, over one
year of follow up, of marked cells in some patients [14].
The ongoing Phase I/II will use C46-transfected autolo-
gous stem cells in up to 10 patients with an independent
indication for autoHSCT, i.e., high-risk AIDS-related lym-
phoma. Use of autologous stem cells for gene transfer cur-
rently requires a biosafety reduced S3 laboratory
environment for the transgene introduction. Future gene
therapy approaches may involve allogeneic transplants,
obviating the need for laboratory conditions of high
safety levels, and exploiting the graft-versus-neoplasm
effect in patients with malignancies.
Recruitment of patients into this type of studies should be
facilitated by the nationwide and international activities
of the German Competence Network HIV/AIDS, repre-
sented by K Jansen (Bochum, Germany) at this meeting.
Conclusion
CCR5-negative stem cell transplantation and transgenic
approaches to HIV therapy hold great promise for future
curative interventions in HIV patients. Replacing lifelong
HAART by a once-in-a-lifetime treatment would have
numerous benefits for patients and the health care system.
If the results published by Hütter et al could be repro-
duced in a few additional HIV-infected leukemia patients,
and the legal questions associated with the use of registry
donors are resolved, the way would be open for intensi-
fied and pre-emptive CCR5-delta32 donor screening for
patients with HIV and malignant diseases.
Similar considerations apply to the described gene thera-
peutic approach, which may be adopted more widely due
to the opportunity to use autologous stem cells. Further
experiences with CCR5-targeted stem cell therapies will
probably encourage the treatment of selected populations
of young HIV-positive patients with multi-resistant infec-
tion and exhaustion of CD4 cells, as well as HIV-infected
pediatric patients with rapidly progressing disease.
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